2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era– Tweetorial #6




Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Biogen.


Management of Management of secondary progressive multiple sclerosis (SPMS)


Physicians who treat patients with MS are challenged to select the disease-modifying therapy (DMT) that is best for an individual patient based on the person’s disease activity, preferences, and goals. In the absence of head-to-head trials showing superiority for any single DMT, appropriate initial treatment selection must be made on a patient-by-patient basis that incorporates patient preferences and goals as well as efficacy and potential adverse events. For patients with highly active disease, more favorable outcomes can be achieved with a high-efficiency compound and should be considered as the initiating agent. Currently, 18 DMTs encompassing a wide variety of efficacy levels and safety profiles are available in the United States. Clinicians need to be familiar with each in order to tailor treatment selection to the individual across the disease continuum.

Through this activity, participants will gain insights on optimal strategies for starting, switching, and stopping treatments throughout the MS disease course based on criteria unique to each patient.

This is a Twitter-based tutorial designed to provide key information in an accessible format and location.


Aaron Boster, MD
Founder and President
The Boster Center for Multiple Sclerosis
Columbus, Ohio


Barry A. Singer, MD
Director, The MS Center for Innovations in Care
St. Louis, Missouri


Release date: November 24, 2021
Expiration date: November 24, 2022
Estimated time to complete activity: 0.25 hour



This program is intended for MS specialists, neurologists, internists, nurse practitioners, and physician assistants who are involved in the care of patients with MS.


Upon completion of this educational activity, participants should be able to:

  • Recognize the importance of early diagnosis & treatment in reducing disability progression among patients with MS
  • Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, & patient preference
  • Evaluate the latest data on the efficacy, safety, & dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS

There are no fees for participating and receiving CME credit for this activity. During the period of November 24, 2021 through November 24, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Physician Continuing Education 

Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.25 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Aaron Boster, MD
Consulting Fees: EMD Serono, Genentech, Genzyme​, Novartis
Speakers’ Bureaus: EMD Serono, Genentech, Genzyme​

Barry A. Singer, MD
Consulting and/or Speaking Fees: AbbVie, Alexion, Bayer, Biogen, Bristol Myers Squibb (Celgene), EMD Serono, Janssen, Genentech, Greenwich Biosciences, Novartis, Roche, Sanofi Genzyme, Teva, TG Therapeutics
Institution Research Grants: AbbVie, Alkermes, Bayer, Biogen, MedImmune, Novartis, Roche, Sanofi Genzyme

The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Continue to Pretest